Citius Pharmaceuticals (CTXR) Upgraded to Hold at Zacks Investment Research
Citius Pharmaceuticals (NASDAQ:CTXR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.
According to Zacks, “Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care and prescription products. Citius Pharmaceuticals, Inc. is headquartered in Cranford, New Jersey. “
Separately, HC Wainwright started coverage on shares of Citius Pharmaceuticals in a report on Wednesday, May 23rd. They issued a “buy” rating and a $11.00 price target for the company.
Citius Pharmaceuticals (NASDAQ:CTXR) last announced its quarterly earnings results on Tuesday, August 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.13. equities analysts expect that Citius Pharmaceuticals will post -1.43 EPS for the current fiscal year.
In other news, insider Myron Z. Holubiak purchased 784,314 shares of the firm’s stock in a transaction dated Monday, August 13th. The stock was bought at an average price of $1.28 per share, with a total value of $1,003,921.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
An institutional investor recently raised its position in Citius Pharmaceuticals stock. Sabby Management LLC boosted its stake in Citius Pharmaceuticals Inc (NASDAQ:CTXR) by 205.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 641,201 shares of the company’s stock after acquiring an additional 431,070 shares during the quarter. Citius Pharmaceuticals accounts for 0.2% of Sabby Management LLC’s portfolio, making the stock its 16th largest position. Sabby Management LLC owned approximately 6.01% of Citius Pharmaceuticals worth $1,988,000 as of its most recent filing with the Securities and Exchange Commission. 6.55% of the stock is owned by institutional investors and hedge funds.
Citius Pharmaceuticals Company Profile
Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok product, which has completed Phase IIb clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido product, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.
See Also: Outstanding Shares
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.